An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning β-cell survival and cardiovascular conditions in diabetic patients

Abhay Srivastava1 · Cheryl Rockman-Greenberg2 · Niketa Sareen1,3 · Vincenzo Lionetti3 · Sanjiv Dhingra1

Received: 15 September 2021 / Accepted: 16 February 2022 / Published online: 2 March 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
A significantly high percentage of hospitalized COVID-19 patients with diabetes mellitus (DM) had severe conditions and were admitted to ICU. In this review, we have delineated the plausible molecular mechanisms that could explain why there are increased clinical complications in patients with DM that become critically ill when infected with SARS-CoV2. RNA viruses have been classically implicated in manifestation of new onset diabetes. SARS-CoV2 infection through cytokine storm leads to elevated levels of pro-inflammatory cytokines creating an imbalance in the functioning of T helper cells affecting multiple organs. Inflammation and Th1/Th2 cell imbalance along with Th17 have been associated with DM, which can exacerbate SARS-CoV2 infection severity. ACE-2-Ang-(1–7)-Mas axis positively modulates β-cell and cardiac tissue function and survival. However, ACE-2 receptors dock SARS-CoV2, which internalize and deplete ACE-2 and activate Renin-angiotensin system (RAS) pathway. This induces inflammation promoting insulin resistance that has positive effect on RAS pathway, causes β-cell dysfunction, promotes inflammation and increases the risk of cardiovascular complications. Further, hyperglycemic state could upregulate ACE-2 receptors for viral infection thereby increasing the severity of the diabetic condition. SARS-CoV2 infection in diabetic patients with heart conditions are linked to worse outcomes. SARS-CoV2 can directly affect cardiac tissue or inflammatory response during diabetic condition and worsen the underlying heart conditions.

Keywords Diabetes · COVID-19 · SARS-CoV2 · β-Cell death · Disease severity · Treatment

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ACE | Angiotensin converting enzyme |
| ADAM-17/TACE | ADAM metallopeptidase domain-17/Tumor necrosis factor-α-converting enzyme |
| AMPK | Adenosine monophosphate-activated protein kinase |
| Ang | Angiotensin |
| AP2 | Adaptor protein complex-2 |
| ARB | Angiotensin receptor blocker |
| ARDS | Acute respiratory distress syndrome |
| COVID-19 | Coronavirus disease 2019 |
| eNOS | Endothelial nitric oxide |
| FIPV | Feline infectious peritonitis (corona) virus |
| FGF | Fibroblast growth factor |
| GCSF | Granulocyte colony-stimulating factor |
| GMCSF | Granulocyte-macrophage colony-stimulating factor |
| HbA1C | Glycated haemoglobin |
| HERO | Health care worker prophylaxis against COVID-19 |
| HNF | Hepatocyte nuclear factor |
| ICU | Intensive care unit |
| IFN | Interferon |
| IL | Interleukin |
Background

Prevalence of diabetes and cardiovascular complications in COVID-19

Diabetes mellitus (DM) is a collection of metabolic disorders characterized by hyperglycaemia resulting from defects in insulin secretion, action or both, owing to disturbance in carbohydrate, fat and protein metabolism. Long standing poorly controlled DM results in complication of eyes, kidneys, nerves, blood vessels and heart [1]. Current statistics by the international diabetes federation atlas 2019 project that nearly 463 million or 9.3% of adults worldwide have diabetes, which may ascend to 700 million or one in every ten adults by 2045 [2].

The outbreak of SARS-CoV-2, COVID-19 has seen successive epicenters that initiated from China to Europe to North America and followed by its progression to developing countries like Brazil and India. The pandemic started in China and in a comprehensive report of 138 patients hospitalized in the Wuhan district, a trend was observed where 22.2% and 25% of all patients requiring admission to intensive care units (ICU) were having diabetes and cardiovascular disease, respectively [3]. Similar data from Shanghai China reported 19.2% cases with critical pneumonia had diabetes and 30.8% had heart conditions [4]. In more recent reports; first originating from Wuhan, Hubei, China, 24.9% of cases with severe COVID-19 symptoms were diabetic out of 193 critical patients and 27.1% of these patients with SARS-CoV2 infection had cardiovascular disease, which was significantly higher than non-diabetic patients [5]. A second report from Taizhau, Zhejiang, China reported 16.3% diabetic patients among the severely ill COVID-19 patients, where 60.5% patients presented chest tightness as one of their symptoms [6]. The major epicenter of this outbreak in the European Union was at Italy. In one of the early reports in February from Pavia, Italy, 15.9% and 25% COVID-19 positive cases were patients with diabetes and heart disease, respectively [7]. Another report coming from the Lombardi region in Italy suggested that out of 1591 COVID-19 positive cases with critical symptoms requiring ICU admission, 17% were diabetic patients and 21% patients had cardiovascular disease [8]. Among all the fatalities in Italy a random number of 355 cases were screened for their comorbidities, and 126 (35.5%) were observed to have diabetes and 30% had ischemic heart disease [9]. The most alarming epicenter originated at USA where a recent report based from the city of New York, of 5700 COVID-19 positive patients who were hospitalized, 1808, i.e. 33.8% patients were found to have diabetes and approximately 56.6% patients were having hypertension and 18% with other heart diseases [10]. A hospitalization surveillance network for the month of March 2020 in the USA found a total of 28.3% diabetic patients and 27.8% with cardiovascular disease in their cohort of hospitalized COVID-19 positive cases [11] (Tables 1 and 2). Similar reports have been emerging from many other affected regions throughout the globe.

Immune imbalance and inflammation are direct effectors of deteriorating β-cell survival and cardiovascular conditions in diabetes

Viral infections as an environmental factor causing diabetes

Viral infections are categorized as one of the main environmental factors in developing type 1 DM. There have been many RNA viruses that are reported to be associated with the development of type 1 DM in humans. Coxsackie A/B viruses, Rubella viruses, Retrovirus and Rota viruses are among the reported viruses [12]. Previous studies have demonstrated that viral infections in β-cells cause prolonged presence of viral proteins within these cells. Also, β-cells have decreased defensive capacity against viral infections when compared to other neighboring endocrine cells. When these viral protein antigens mixed with β-cell specific antigens are presented to the host immune system, the generated
immune response starts acting on the β-cells, thereby developing autoimmunity [13]. Further, the fact that viral proteins tend to persist longer in human β-cells suggests their lower clearance rate of viral particles [14]. Type 1 DM and autoimmunity emerging due to viral infections has been linked with genetic predisposition where function and regulation of genes involved in antiviral response, host immunity, β-cell structure and function affect the onset of the disease. The genetic variations favor virus induced type 1 DM when genes involved in viral particle recognition, viral particle clearance, antiviral response and its downstream signaling have distinct DNA variants [15].

**Immune imbalance and inflammation from viral infection is directly related to severity and new onset in diabetic patients**

The β-cells infected by viruses lead to a cytotoxic immune response by presenting β-cell specific antigens to lymph nodes upon their death. This epitope spreading can induce an autoimmune response towards β-cells in the infected host [16]. In diabetic animal models, it has been confirmed that viral infections attract natural killer cells and T cells that produce inflammatory cytokines like interferon-γ, TNF-α and IL-1β leading to the destruction of β-cells [17]. Further, if viral antigens have homology to β-cell epitopes it can accelerate the incidence of type 1 DM caused due to molecular mimicry [18]. Another mechanism that augments to β-cell death via the host immune system is bystander activation, where viral infections in the surrounding tissues produce inflammatory cytokines from their cell death. These cytokines would activate T cells specific to β-cells within pancreas or lymph nodes resulting in β-cell death [15, 19].

How SARS-CoV2 affects type 1 diabetic patients is yet to be confirmed. The presence of ACE-2 receptors on islet β-cells makes these cells a direct target for SARS-CoV2 spike protein binding, subsequent infection and ensuing deleterious effects. The cellular death due to viral infections causes inflammatory response. This altered cytokine/chemokine profile around various tissue systems affects their characteristics and normal function, which is reflected in the clinical characteristics reported so far [5]. More importantly the fact that SARS-CoV leads to β-cell dysfunction causing acute diabetes [20], along with the above discussed case report of young patient developing new onset diabetes after SARS-CoV2 infection is sufficient to acknowledge the connection between SARS-CoV2 in diabetic disease pathogenesis and patient severity.

---

**Table 1** Prevalence of diabetes mellitus as a comorbidity in Covid-19 positive cases globally

| Report Region | Parameters of diabetic patients with Covid-19 | Parameters of patients in ICU with severe Covid-19 symptoms | **Cardiovascular disease within ICU/severe condition (%)** |
|---------------|---------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|
| Wuhan, China  | 10.1                                       | 22.2                                                      | 16.7                                                     |
| Hubei, China  | 7.5                                        | 19.2                                                      | 30.8                                                     |
| Wuhan, China  | 24.8                                       | 34.78                                                     | 27.1**                                                   |
| Taizhou, Zhejiang, China | 6.9 | 14.2 | 60.5$ |
| Lombardy, Italy | 15.9 | NR | 35.29 |
| Italy         | 16.3                                       | NR                                                        | 21                                                       |
| New York, USA | 35.5                                       | NR                                                        | Hypertension 56.6                                       |
| USA (14 states) | 178.8                                      | NR                                                        | Coronary artery disease 11.1                            |
| NR not reported | *Parameters of diabetic patients with Covid-19 | $Parameters of patients in ICU with sever Covid-19 symptoms | **Cardiovascular disease within ICU/severe condition (%)** |
|               | $ Patients presenting chest tightness      |                                                           | Hypertension 56.6                                        |

NR = not reported
* = Parameters of diabetic patients with Covid-19
$ = Parameters of patients in ICU with sever Covid-19 symptoms
** = Cardiovascular disease with diabetes
$ = Patients presenting chest tightness
SARS-CoV2 infection causes T cell imbalance and inflammation which is associated to increase disease severity in diabetic condition

COVID-19 and cytokine storm

Earlier studies have relayed elevated levels of pro-inflammatory cytokines in patients infected with SARS-CoV and MERS-CoV. Similarly, with respect to SARS-CoV2, 41 COVID-19 confirmed cases were hospitalized, of which 20% had diabetes. The patients who were admitted had higher plasma concentration of cytokines and growth factors such as TNF-α, PDGF, MCP-1, MIP-1A, MIP-1B, IP-10, IFN-γ, basic FGF, GCSF, GMCSF, VEGF, IL-1β, IL-1RA, IL-7, IL-8, IL-9 and IL-10 than non-infected patients. Further, the plasma levels of following cytokines were higher in the patients admitted to intensive care units (ICU): TNF-α, MCP-1, MIP-1A, IL-2, IL-7, IL-10, GCSF and IP-10 [21]. There is a marked difference in the cytokine profile between the COVID-19 infected patients in ICU compared to non-ICU COVID-19 confirmed cases, which strongly indicates the connection between the cytokine storm and disease severity. Further, this cytokine storm would inevitably lead to multi-organ dysfunction due to hyper-inflammation, which in fact is observed in most of the critical COVID-19 cases globally [22].

SARS-CoV2 infection causes T cell imbalance

SARS-CoV2 infections have caused severe clinical conditions in many patients. In one such report, 286 COVID-19 patients out of 452 positive cases developed severe disease [23]. In these severe patients lymphocytopenia was observed based on immune cell phenotyping. It was observed that not only CD4+ T cell population decreased in these patients but also the ratio of naive to memory CD4+ T cells increased. These reports also confirmed decrease in the number of T regulatory (T regs) cell populations including induced T regs that restrain allergic response and naïve T regs which regulate autoimmunity. These alterations in the levels of immune cells caused an imbalance in functioning of the immune system. The reduced T reg population may further aid in enhancing the inflammatory damage. This along with increased neutrophil to lymphocyte ratio and higher

### Table 2 Clinical biochemical parameters of positive Covid-19 cases globally

| Report | [3] | [4] | [5] | [6] | [7] | [10] |
|--------|-----|-----|-----|-----|-----|------|
| WBC count, ×10^9/L | 6.6 (3.6–9.8) (median) | 18.6% ≤ normal range & 0.3% ≥ normal range | 7.99 (5.90 to 13.04) | 6 (4.44, 7.40) | 50% leukopenia (white blood cell count <5000 cells/mm^3) | 7.0 (5.2–9.5) |
| Neutrophil count, ×10^9/L | 4.6 (2.6–7.9) | 2.1% ≤ normal range & 0.4% ≥ normal range | 7.25 (4.33 to 11.81) | 4.5 (2.7, 5.6) | NR | 5.3 (3.7–7.7) |
| Lymphocyte count, ×10^9/L | 0.8 (0.5–0.9) | 10.8% ≤ normal range & 0.8% ≥ normal range | 0.54 (0.42 to 0.93) | 0.9 (0.6, 1.1) | 88.63% Lymphopenia (lymphocyte count <1500 cells/mm^3) | 0.88 (0.6–1.2) |
| Monocyte count, ×10^9/L | 0.4 (0.3–0.5) | NR | NR | 0.4 (0.3, 0.5) | NR | NR |
| Platelet count, ×10^9/L | 142 (119–202) | NR | 161.0 (126.5 to 232.5) | 192 (142, 259) | 43.18% Thrombocytopenia (platelets <150,000/mm^3) | NR |
| D-dimer, mg/L | 0.414 (0.191–1.324) | NR | 2.6 (1.0 to 2.1) | 0.32 (0.21, 0.49) | NR | 0.438 (0.262–0.872) |
| C reactive protein | NR | 42.9% ≥ normal range | NR | 4.7 mg/mL (1, 26.78) | 18.18% CRP elevated (CRP > 10 mg/dL) | 13.0 (6.4–26.9) mg/dL |

NA Not reported
*Parameters of Diabetic Patients with Covid-19
Parameters of Patients in ICU with sever Covid-19 symptoms
levels of pro-inflammatory cytokines are related to hyper-inflammation and infection, which is consistent with cases of critical patients in other COVID-19 reports [3, 23]. In SARS-CoV2 COVID-19 infected patients it is noticed that inflammatory cytokines like IFN-γ and MCP-1 activate Th1 cells, which triggered specific immunity. However, on the other hand, these patients also express IL-4 and IL-10 which are secreted by Th2 cells, responsible for suppressing inflammatory responses [24]. Further, Th17 cells would get activated due to various cytokines such as IL1-β and TNF-α present within the cytokine storm. Th17 themselves release IL-17, IL-21, IL-22 and GCSF. IL-17 is a pro-inflammatory cytokine which is broadly associated with autoimmunity and inflammatory diseases whereas GCSF promotes development of granulocytes and recruit neutrophils [25]. Another aspect of immune response relevant with COVID-19, SARS-CoV2 viral infection is macrophage activation syndrome (MAS), which is characterized by the presence of elevated levels of IL-6, IL-1β, IFN-γ and TNF-α along with ferritin. This is highly associated with lung hyper-inflammation and ultimately development of acute respiratory distress syndrome (ARDS) [26].

**T cell imbalance and inflammation is also a characteristic clinical feature in both type 1 and 2 diabetes mellitus**

**T cell imbalance and inflammation in type 1 diabetes mellitus** The Th1/Th2 cells imbalance is greatly associated with diabetic condition. Th1 cells stimulated by IFN-γ and IL-12 are essential in activation of macrophages and pathogen clearance; whereas Th2 cells get stimulated by IL-4, which regulate immune response towards allergies. Previously, in a rodent study it was reported that type 1 DM, which is an autoimmune disorder, observed an increase in stimulated Th1 cells in response to increased level of IFN-γ. IFN-γ level is also elevated in viral induced type 1 DM and is also observed in severe cases with COVID-19. However, in response to SARS-CoV2 infections there is no change in IL-4 levels resulting in an imbalance between Th1/Th2 cells. This disturbance in the balance results in increased inflammation and MAS. Further, IFN-γ is implicated in up regulating MHC class 1 and II expressions and homing of Th1 cells towards pancreatic endocrine cells in non-obese diabetic (NOD) mice, thereby implicating itself in the progression of type 1 DM [21, 27]. Th17 cells that produce IL-17 have been previously confirmed to be present in abundance in type 1 diabetic human pancreas [28]. Further, elevated levels of IL-6 and IL-1β as mentioned above in COVID-19 severe cases, can promote Th17 development which along with pro-inflammatory cytokines plausibly lead to islet inflammation causing β-cell death [29]. T cells that can express both IFN-γ and IL-17 are called Th1/17 cells and have also been identified in type 1 diabetic patients [30]. This immune system imbalance may lead to β-cell dysfunction resulting in new onset diabetes in SARS-CoV2 infections.

**T cell imbalance and inflammatory cytokines linking type 2 diabetes mellitus** The elevated levels of IL-17 have also been detected in patients with type 2 diabetes, which have been linked to inflammation in adipose tissue. IL-17 regulates expression of TNF-α and NF-kB, which can lead to elevated pro-inflammatory cytokines expression causing chronic inflammatory responses at systemic level. This plays an essential role in development of insulin resistance in type 2 diabetic patients [31]. White adipose tissue is compromised for its secretory cytokine profile which involves several pro-inflammatory cytokines [32]. Further an imbalance in the immune system leading to changes in the macrophage phenotype has been observed with a shift from anti-inflammatory M2 type to pro-inflammatory M1-type [33]. There has been a direct molecular link that has previously proven the role of inflammatory cytokines in inducing insulin resistance in the peripheral tissue [34]. COVID-19, SARS-CoV2 viral infection induced cytokine storm along with the systemic immune cell and cytokine imbalance in diabetic patients would make their clinical state more aggravated and severe as identified in previous clinical reports and case studies. An insight into SARS-CoV2 infection and inflammation mediated severity in diabetes will be discussed in later sections.

**Immune cell imbalance leading to inflammation in diabetic state causes cardiomyopathy**

Patients with DM develop abnormality in myocardial structure and function, mainly in ventricles, leading to heart failure, even in absence of hypertension or any coronary artery or valve disease. Increase in glycemic and insulin index along with cardiac insulin resistance in diabetic patients lead to elevated levels of inflammation and oxidative stress in the cardiac tissue, which result in cardiac cell death and disassembly. All these factors cumulate towards hypertrophy, fibrosis and stiffness of the cardiac tissue leading towards dysfunction and heart failure. The initial phase of diabetic cardiomyopathy is characterized by development of cardiac diastolic dysfunction due to inflammation, oxidative stress and activation of RAAS pathway induced by glucotoxicity, cardiac insulin resistance and, metabolic and Ca²⁺ signaling dysregulation. The later phase includes progression towards clinical heart failure by worsening of diastolic dysfunction through LV hypertrophy and cardiac tissue disassembly directly affecting heart function.

Diabetic pathophysiology induces perturbations in the innate immune system thereby stimulating the pro-inflammatory cytokines which aid in the development and progression of cardiac myopathy [35]. Increased ROS, AGEs and

---

1685
activation of RAS pathway (discussed in the later section) in diabetic condition within the cardiac tissue can upregulate expression of transcription factors like NF-KB, which can further regulate expression of pro-inflammatory cytokines and cell death. Activation of NF-KB in murine diabetic models has previously shown to increase ROS mediated endothelial and myocardial cell dysfunction and death in cardiac tissue. Further, due to increased ROS, macrophages accumulated within the cardiac tissue undergo pro-inflammatory M1 polarization, which further aids in promoting tissue inflammation by pro-inflammatory cytokines and growth factors that further stimulate fibrosis. Further, impaired macrophage function with respect to its phagocytosis and chemotactic activity has been previously observed in diabetic patients [36].

In diabetes, glucotoxicity and oxidative stress activate immune cells to create inflammatory niche in cardiac tissue. Presence of activated leucocytes with high production of ROS has been observed post MI in diabetic coronary microcirculation. Neutrophils in diabetic condition secrete pro-inflammatory cytokines, and form neutrophil extracellular traps which contribute towards sustained inflammatory response and prevent wound healing. CAD onset has been previously observed to be associated with increase in Th1, Th17 and Th22 lymphocytic subsets. Th1 and Th17 cells and their associated cytokines were upregulated, whereas Th2 population was suppressed in diabetic patients manifesting CAD. Further, a decline in Treg population that helps in inflammatory homeostasis and prevention of chronic inflammation is observed to have declined in diabetic patients associated with heart failures. Hence, in summary metabolic perturbations in diabetic condition leads to a systemic immune imbalance which results in activation of pro-inflammatory mechanisms resulting in cardiac inflammation thereby causing myocardial stiffness, disassembly, dysfunction and cell death. All of which gradually leads to heart failure in the chronic diabetic inflammatory state.

COVID-19, ACE-2 receptors and their relation with diabetes and cardiovascular disorders

ACE-2 molecular machinery

Classically renin-angiotensin system (RAS) entails the conversion of liver angiotensinogen to angiotensin-I (Ang-I) by renin in the kidney. Ang-I is further converted to angiotensin-II (Ang-II) by angiotensin-converting enzyme (ACE). Ang-II promotes electrolyte reabsorption from kidney and regulates vasoconstriction [37]. Ang-II can also induce ROS production by activating NAD(P)H oxidase [38]. In terms of promoting inflammation, Ang-II and RAS signaling stimulate the production of various pro-inflammatory cytokines and chemoattractant like MCP-1. It also triggers an increase in vascular permeability by elevating VEGF secretion to increase infiltrating immune cells [39]. ACE-2 is monocarboxy-peptidase, zinc metalloprotease enzyme with a 42% homology with ACE. The membrane bound ACE-2 is cleaved at its ectodomain by ADAM-17 to generate its soluble form. ACE-2 converts Ang-II to Ang-(1–7). Ang-(1–7) binds to Mas receptor, which activates the release of bradykinin, nitric oxide, prostaglandin and inhibits the release of norepinephrine, which results in vasodilation [40, 41]. The earlier reports confirm that ACE-2 presents itself as a receptor for SARS-CoV and several recent reports on COVID-19 pandemic now suggest that ACE-2 is the receptor for SARS-CoV-2 COVID-19 as well [42, 43] (Fig. 1).

Mechanism of ACE-2 receptor in diabetic complications

The RAS system has been reported to be in a hyperactive state in the diabetic condition [40]. The inhibition of RAS has shown amelioration in diabetic condition by increasing insulin sensitivity and glucose uptake in both adipose and muscle tissue. In liver and pancreas, it has been reported to prevent fibrosis and oxidative damage along with increase in insulin release from the pancreas. ACE-2 counter the RAS pathway and abates the progression of several pathological processes in various tissues in the diabetic condition [40]. In diabetic condition, elevated levels of ACE were observed in serum, heart, lung, and liver, while ACE-2 was significantly increased in serum, liver and pancreas [44]. Further, diabetic nephropathy follows deletion of ACE-2 gene in type...
1 diabetic mice [45]. Also, Mas knockout mice develop insulin resistance and faulty glucose uptake thereby associating the ACE-2/Ang-(1–7)/Mas axis with type 2 DM [46]. Ang-(1–7) in skeletal muscles could enhance insulin sensitivity and insulin dependent glucose uptake thereby ameliorating insulin resistance [47].

**Renin-angiotensin system in diabetes induces cardiovascular disorders**

RAS has a profound effect on the development of cardiovascular complications in diabetic state. Hyperglycemia induced increase in Ang-II levels has been previously observed in cardiac tissue. Ang-II has an adverse effect on insulin receptor and downstream insulin signaling, thereby aiding the insulin resistance condition in the cardiac tissue [48]. Further, Ang-II via AT-1 receptor induced a signaling cascade involving JAK-STAT pathway, MAP kinase pathway and inositol phosphate recruiting NF-AT3 to promote proliferation of cardiac fibroblasts. Ang-II via AT-1 also activates p53 which triggers apoptosis in these cells causing cardiac fibrosis [49]. In response to oxidative stress and inflammatory conditions in the diabetic condition, NF-KB is activated in the cardiac tissue which further regulates and enhances the pro-inflammatory mediated tissue damage. It is reported that Ang-II induces the expression of NF-KB through TLR-4/JNK signaling in the cardiac tissue, which further leads to endothelial dysfunction, vascular remodeling and stiffness [50]. Patients with diabetic condition are often treated with ACE inhibitors and Ang-II type 1 receptor blockers (ARBs) along with other antidiabetics like thiazolidinedoines which all upregulate the expression of ACE-2. Similarly, patients with hypertension are also treated with ACE inhibitors and ARBs. This condition is uniquely poised for developing a more severe and alarming SARS-CoV2 infection among such patients [51].

**ACE-2 and beta cell survival in diabetic patients**

The islets of Langerhans makes up the endocrine part (1–2%) of the whole pancreas, and 70–90% of islet is comprised of insulin producing β-cells. The acinar cells along with endothelial cells which make up the microvascular part that supply blood, together makes up 98% of the exocrine pancreatic tissue [52]. The β-cells are known to have low levels of antioxidant enzymes when compared to other types of cells present in the endocrine pancreas, which makes them specifically vulnerable to oxidative stress leading to cell death [53]. The ACE-2 receptors are expressed in the exocrine (acinar) and endocrine (islets) system of the pancreas [54]. It is reported that ACE-2 knockout mice demonstrate decreased capacity of insulin secretion in response to glucose [55]. Further, ACE-2 gene therapy in 8-week db/db mice improved blood glucose, increased islet function, β-cell proliferation and survival. However, it only improved glucose homeostasis with no effect on β-cells when mice were given gene therapy after 16 weeks [56]. It was reported that disruption in glycemic homeostasis with pancreatic β-cell dysfunction is caused due to decreased ACE-2 levels. Therefore, lowered ACE-2 levels would elevate serum Ang-II which would increase β-cell Ang-II receptors and augment the RAS pathway, thereby increasing oxidative stress in β-cells. However, ACE-2 gene therapy ameliorated the above condition thereby affecting β-cell survival. In this study, the restoration of ACE-2 enzyme expression and activity was associated with decreased β-cell oxidative stress, increased glucose stimulated insulin secretion (GSIS) and improved overall β-cell function [57]. In a recent study, deficiency of ACE-2 caused negative impact on β-cell mass and proliferation in mice [58]. It was observed that ACE-2-Ang-(1–7)-mas axis decreases pro-inflammatory cytokine levels including interleukin-6 (IL-6) and interleukin-8 (IL-8) and increases anti-inflammatory cytokines including interleukin-10 (IL-10) levels. This was associated with increased expression of P13K/AKT pathway and eNOS in the exocrine pancreas as well as improvement in pancreatic function [59]. In another study, it was concluded that ACE-2-Ang-(1–7)-mas axis inhibits pancreatitis by downregulating pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α and abating p38MAPK/NF-KB pathway [60]. The above axis activates the Akt/NOS/NO pathway in endothelial cells, which is essential for pancreatic homeostasis, thereby improving β-cell survival and function [61]. However, presence of ACE-2 on β-cells and other tissues would make these tissue systems more susceptible and impacted during a SARS-CoV-2 infection (Fig. 2).

**COVID-19, ACE receptors and their relation to severity of cardiovascular condition in diabetes patients**

**SARS-CoV2 structure proteins and ACE-2 receptor**

The SARS-CoV-2 COVID-19 viral RNA codes for 4 vital structural proteins viz. transmembrane spike glycoprotein (S), membrane (M), envelope (E) and nucleocapsid protein (N) (Fig. 1). The S protein is a homotrimer which allows the virus to anchor to the host cellular surface and fuse with its membrane. It has two domains, S1 which has a receptor binding domain (RBD) and S2 which assists the viral and membrane fusion. Further, a cellular serine protease, i.e. Tmprss2 is required for priming and cleaving the S protein at S2’ site of S1/S2, followed by S2 mediated viral fusion [62]. As described in the above sections, in diabetic condition there is elevation in the expression of
ACE-2 receptor at a multi organ level, which would possibly lead to an increase in the cellular tropism involved with SARS-CoV-2. Further, ACE-2 counters the RAAS pathway as discussed earlier in cardiovascular disorders. The internalization of ACE-2-virus complex decreases the ACE-2 receptors on the cell surface along with inhibition of ACE-2 by unknown viral particles [63], thereby rendering the ACE-2/Ang-(1–7)/mas axis ineffective making the cardiovascular and diabetic condition under the influence of SARS-CoV-2 COVID-19 more severe (Fig. 1).

Role of ADAM-17 in relation to COVID-19, diabetes and its cardiovascular complications

TNF-α converting enzyme (TACE) known as ADAM-17 is a Zn metalloprotease of the adamalysin subfamily. It activates TNF-α, which is responsible for chronic inflammation. ADAM-17 is known to activate other cytokines and receptors. ACE-2 being one such receptor is cleaved by ADAM-17 leading to enhanced activation of RAS pathways that leads to oxidative stress and subsequent inflammation. RAS activation involves phosphorylation of ADAM-17 that catalyzes the shedding of ACE-2 from the cell membrane thereby creating a positive feedback loop. Increase in ADAM-17 expression has been reported in cardiac tissue under the influence of ectopic Ang-II [64], which is followed by significant reduction in membrane bound myocardial ACE2 and rise in plasma ACE2 levels. Wang et al., have previously shown that silencing of ADAM-17 prevented progression of cardiac hypertrophy and fibrosis in presence of Ang-II [65]. During COVID-19, SARS-CoV2 viral infection, viral binding to ACE-2 receptors decreases the overall receptor expression that leads to abatement of ACE-2 mediated protective response and activation of ADAM-17 by activation of RAS pathway. In diabetic condition it was observed that ADAM-17, that causes shedding of ACE-2 does not deplete it from the surface of islets within pancreas, which during COVID-19, SARS-CoV2 viral infection serves as docks for the viral entry followed by inflammatory responses as described above [66]. In previous studies with SARS-CoV, it has been observed that viral entry was severely hampered on downregulating the expression of ADAM-17. Hence, it is possible that for the SARS-CoV-2 infection, inhibition of ADAM-17 may play a vital role in restricting viral entry and retaining ACE-2 function [43].

Impaired β-cell and cardiac function due to glycated hemoglobin (HbA1c) levels in SARS-CoV2 infections

Clinical description of COVID-19 patients throughout the world has shown higher than normal levels of glycated hemoglobin. Interestingly, an inverse relationship between glycated hemoglobin levels and β-cell function has been well established. Increase in HbA1c levels correspond to a significant decrease in insulin sensitivity and β-cell function as shown in Mexican American subjects [67]. Thereafter, in more than 10,000 subjects, a direct correlation was established between increase in insulin resistance and loss of β-cell function with an increase in HbA1c levels independent of gender, age, or body mass index [68]. This has been
further validated in non-diabetic off springs of type 2 diabetic individuals where in response to elevated HbA1C levels acute loss of insulin sensitivity followed with decreased β-cell function was observed [69]. Previous clinical studies have shown a direct link between reduction in HbA1C levels corresponding to a reduction in heart failure risk. It was seen that a 1% reduction in HbA1C reduces 16% risk of manifesting heart failures [70]. Another study established that glycated hemoglobin levels above 6% have a direct implication with an increased risk of developing cardiovascular complications [71]. Further, with respect to COVID-19 pandemic, elevated levels of HbA1C has been clinically associated with inflammation, thrombosis and death rate suggesting that patient severity was directly associated with elevated HbA1C levels [72]. Hence, an existing robust correlation can be drawn between the disease pathogenesis and its severity presented for heart diseases in diabetic or hyperglycemic patients suffering from SARS-CoV2 infections.

**SARS-CoV2, imbalance in ACE-2/RAS signaling, insulin sensitivity and hyperglycemia leads to β-cell and cardiac tissue dysfunction—a vicious circle**

The relationship between diabetes and SARS-CoV2 infection appears to be bi-directionally correlated. It seems that the infected state becomes more severe in patients with pre-existing diabetes whereas there is also a possibility of new onset diabetes post SARS-CoV2 infection [73]. The cause for either is unclear. However, pathogenic load causing systemic inflammation has been directly linked to insulin resistance and development of type 2 DM [74]. Triglyceride-glucose (TyG) index (marker for insulin resistance) is associated with metabolic disorder was observed to be accompanied with critical patients infected with SARS-CoV2 [75]. ACE-2/Ang-(1–7)/mas pathway is rendered inactive due to internalization of ACE-2 receptors by SARS-CoV2, which activates the Ang-II mediated RAS pathway. Further, progression of SARS-CoV2 triggers RAS pathway to stimulate oxidative stress and inflammation [43]. Moreover, Ang-II has been strongly implicated in promoting insulin resistance by desensitizing the insulin signaling pathway in the peripheral tissue [76]. RAS further aids in the development of insulin resistance in response to pro-inflammatory stimulation [76]. Insulin resistance can increase free fatty acids in circulation from adipocytes which trigger a cascade of events to decrease overall HDL and increase LDL which are both risk factors for cardiovascular diseases [77]. Activation of RAS pathway also triggers elevation in blood pressure along with vasoconstriction and cardiac contractility [78]. Hyperglycemia in SARS-CoV2 infected patients has been directly correlated as an independent risk factor associated with increased severity and mortality [79–81]. Classically it is well understood that systemic hyperglycemic condition leads to glucoxicity, β-cell dysfunction and diabetic cardiomyopathy [82, 83]. It is observed that hyperglycemia upregulates expression of angiotensinogen, ACE and Ang-II [84]. Alternatively, ACE-2 receptors in diabetic condition were upregulated in serum, liver and pancreas in NOD mice [44]. ACE-2 receptor deletion in NOD mice severely affected glucose homeostasis and decreased β-cell function [85]. β-cell dysfunction and their dedifferentiation was observed in a high fat mice model in response to ACE-2 knockout, which gets ameliorated by stimulation of ACE-2/Ang-(1–7)/mas signaling [86]. Susceptibility of β-cells to SARS infection have been previously reported which led to β-cell death followed by acute diabetes [20]. All this indicates that high glucose could lead to an increase in ACE-2 expression in the insulin producing β-cells which then may get adversely affected by the SARS-CoV2. To validate this claim, a recent study has shown that with increased inflammatory stress condition, the expression of ACE-2 receptors on β-cells in human pancreas is preferentially and significantly upregulated making these cells more susceptible and targeted during SRAS-CoV2 infection [87]. Further, we also know that SARS-CoV2 viral spike proteins bind to ACE-2 receptors and both the virus and the receptors are heavily glycosylated [88, 89]. This glycosylation not only facilitates viral selectivity and entry into the cells but also acts as a shield against antibody recognition [90]. It is possible that systemic high glucose may lead to higher glycosylation rates of these molecules thereby worsening the SARS-CoV2 infection state [91]. These evidences indicate that there is a vicious cycle at play where SARS-CoV2 targets the ACE-2 receptors on peripheral tissues increasing insulin resistance and hyperglycemia, which would in turn affect β-cell burn out along with increasing hypertension and increased risk of cardiovascular complications. β-cells by themselves expressing ACE-2 would fall prey to the virus. Further, hyperglycemic condition would increase viral infection in peripheral tissue and β-cells along with activation of RAS pathway would facilitate more adverse patient condition. This would explain the increased deteriorating patient heart condition in existing diabetic patients contracting SARS-CoV2 in COVID-19 patients (Fig. 3).

**SARS-CoV2 hypercoagulability in relation to diabetic cardiomyopathy**

There is an alarming rate of mortality in diabetic patients due to blood clotting and 2/3rd of these patients succumb to MI [92]. Endothelial dysfunction is a characteristic feature in diabetic cardiomyopathy which aids in manifestation of thrombotic events. Since endothelial von Willebrand factor (vWF) expression is increased during exposure to angiotensin II-induced oxidative stress [93], it is conceivable that platelets are highly activated in diabetic condition which
allows increased platelet aggregation and coagulation products. Diabetic patients with insulin resistance, even complicated by cardiovascular diseases, also show elevated levels of clotting factors like fibrinogen, factor VII & vWF [94] and reduced anticoagulating mechanisms like the fibrinolytic system due to abnormal clotting and elevated levels of PAI-1 [77]. Further, an emerging opinion among COVID-19 related research and clinical community is the presence of elevated d-dimer levels in COVID-19 patients connecting to venous thromboembolism and presence of pulmonary emboli in many of the COVID-19 patients [95] (Table 2). This is supported by the fact that activation of coagulation during infection leads to an intense inflammatory response causing multi organ failure. Thrombin creates clots by converting fibrinogen to fibrin and could promote inflammatory response through proteinase-activated receptors (PARs) especially PAR-1. The inhibitors that can suppress this response could be tested and developed as a new therapeutic line for the COVID-19 patients [96].

**Influence of other comorbidities on SARS-CoV2 infected patients**

Disease severity in COVID-19 patients is not just a function of their diabetic state but other comorbidities also have significant influence on patient condition. Hypertension, obesity, cardiovascular and renal disorders are some of the underlying conditions that can influence both severity and survival of COVID-19 patients. Mortality during COVID-19 has been directly linked to underlined disease where more number of underlying diseases increased the mortality rate from 0.8% with no disease, to 48.5% with 3 or more underlying disorders [9]. Obesity has also been associated with a sixfold increase in disease severity among the SARS-CoV2 affected individuals [97]. An increased prevalence of obesity was observed in critically ill COVID-19 patients admitted to ICU [98]. Further, since both diabetes and obesity are characterized with altered cytokine profiles leading to chronic systemic inflammation, they may cause a synergistic effect on enhancing disease severity in COVID-19 patients [99]. In a retrospective study from the Lombardy region in Italy, mortality rate was found to be significantly higher in patients with hypertension that were admitted to ICU, where fewer patients with hypertension were discharged from ICU [8]. 69.4% mortality was observed accompanied with hypertension and 40.5% with diabetes in a report presenting clinical outcomes from New York City [10]. Similarly, mortality rate of 53.8% was observed in non-survivors having both hypertension and diabetes together. 28.2% non-survivors had cardiovascular disorders with diabetic condition [5]. Cardiovascular and metabolic disorders have been observed to accompany increased severity in COVID-19 patients [100]. Proteinuria was observed in 43.9% of COVID-19 patients when hospitalized and 5.1% with acute kidney injury. A high prevalence of elevated serum creatinine, blood urea nitrogen and below normal estimated glomerular filtration rate was observed [101]. Also, acute kidney injury was observed among 80.3% non-survivors with diabetic condition [5]. Hence, presence of other comorbidities along with diabetics can be correlated to an increased severity and mortality rate among COVID-19 patients.
In conclusion, there is a high risk of developing and worsening cardiovascular complications in diabetic patients with SARS-CoV2 infection

In conclusion, we believe that COVID-19, SARS-CoV2 viral infection causes a multi organ distress disease by creating an imbalance between the host cellular and cytokine immune system resulting in a hyper-inflammatory cytokine storm affecting systemic homoeostasis. COVID-19, SARS-CoV2 viral infections in diabetic patients who already have compromised and imbalance immunity lead to further deterioration of their overall condition making it more severe. Further, β-cells are classically susceptible to oxidative stress experience an increase in inflammation and ACE-2 receptor depletion during COVID-19, SARS-CoV2 viral infections, which possibly negatively impacts β-cell function and survival, thereby increasing severity of the disease. Disease severity in COVID-19 patients is not just a function of their diabetic state but other comorbidities also have significant influence on patient condition. Mortality during COVID-19 has been directly linked to underlying disorders where the mortality rate increases from 0.8% with no disease to 48.5% with 3 or more underlying disorders [9]. Cardiovascular disease is one of the underlying conditions that can influence both severity and outcome of older COVID-19 patients [102, 103]. In the previous sections we have discussed prevalence of diabetes in COVID-19 patients; however, the risk of heart failure has also been observed similarly [104]. Sars-CoV2 can directly affect cardiac tissue leading to inflammatory stress response and cardiac dysfunction [105]. However, cardiovascular and metabolic disorders have been observed to accompany increased severity in COVID-19 patients and there is multi-fold increase in cardiovascular disease in diabetic SARS-CoV2 infected patients [100] (Fig. 4). Severity of diabetic patients with SARS-CoV2 infection could lead to pulmonary embolism due to increased D-dimer levels leading to hypercoagulation, causing hypoxia and heart failure [106]. Further, we have previously discussed the role of hyperglycemia in increasing the expression of ACE-2 receptors on cell surface, which would than enhance the susceptibility of cardiac cells to SARS-CoV2 onslaught. SARS-CoV2 binding to ACE-2 activates RAS pathway which in turn triggers oxidative stress and inflammatory pathways leading to hypertension, myocardial arrhythmia and injury in cardiac tissue [107].

Fig. 4 Graphical summary explaining the effect of diabetes and heart disease towards severity of clinical condition during SARS-COV2 infections

In conclusion, there is a high risk of developing and worsening cardiovascular complications in diabetic patients with SARS-CoV2 infection

In conclusion, we believe that COVID-19, SARS-CoV2 viral infection causes a multi organ distress disease by creating an imbalance between the host cellular and cytokine immune system resulting in a hyper-inflammatory cytokine storm affecting systemic homoeostasis. COVID-19, SARS-CoV2 viral infections in diabetic patients who already have compromised and imbalance immunity lead to further deterioration of their overall condition making it more severe. Further, β-cells are classically susceptible to oxidative stress experience an increase in inflammation and ACE-2 receptor depletion during COVID-19, SARS-CoV2 viral infections, which possibly negatively impacts β-cell function and survival, thereby increasing severity of the disease. Disease severity in COVID-19 patients is not just a function of their diabetic state but other comorbidities also have significant influence on patient condition. Mortality during COVID-19 has been directly linked to underlying disorders where the mortality rate increases from 0.8% with no disease to 48.5% with 3 or more underlying disorders [9]. Cardiovascular disease is one of the underlying conditions that can influence both severity and outcome of older COVID-19 patients [102, 103]. In the previous sections we have discussed prevalence of diabetes in COVID-19 patients; however, the risk of heart failure has also been observed similarly [104]. Sars-CoV2 can directly affect cardiac tissue leading to inflammatory stress response and cardiac dysfunction [105]. However, cardiovascular and metabolic disorders have been observed to accompany increased severity in COVID-19 patients and there is multi-fold increase in cardiovascular disease in diabetic SARS-CoV2 infected patients [100] (Fig. 4). Severity of diabetic patients with SARS-CoV2 infection could lead to pulmonary embolism due to increased D-dimer levels leading to hypercoagulation, causing hypoxia and heart failure [106]. Further, we have previously discussed the role of hyperglycemia in increasing the expression of ACE-2 receptors on cell surface, which would than enhance the susceptibility of cardiac cells to SARS-CoV2 onslaught. SARS-CoV2 binding to ACE-2 activates RAS pathway which in turn triggers oxidative stress and inflammatory pathways leading to hypertension, myocardial arrhythmia and injury in cardiac tissue [107].

Author contributions Conception (AS & SD), Designing (AS & SD), Literature survey (AS & NS), Writing and Final Approval of Manuscript (AS, CRG, NS, VL and SD).

Funding This work is funded by Canadian Institutes of Health Research (CIHR) (Grant No. PJT156148).

Data availability All the data related to this review article are available in this article and respective cited literature.

Code availability Not Applicable.

Declarations

Conflict of interest Authors report no financial or non-financial conflict of interests.

Ethical approval and consent to participate This is an original review article where no ethical approval or informed consent was applicable.

Consent for publication All authors have read and agreed to the publication of this manuscript.

References

1. Karamanou M, Protopogerou A, Tsoucalas G, Androutsos G, Poullakou-Rebelakou E (2016) Milestones in the history of diabetes
mellitus: the main contributors. World J Diabetes 7:1–7. https://doi.org/10.4239/wjd.v7.i1.1

2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diab. Res. Clin. Pract. 157:107843

3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. https://doi.org/10.1001/jama.2020.1585

4. Yu X, Sun X, Cui P, Pan H, Lin S, Han R, Jiang C, Fang Q, Kong D, Zhu Y, Zheng Y, Gong X, Xiao W, Mao S, Jin B, Wu H, Fu C (2020) Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis. https://doi.org/10.1111/tbed.13604

5. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, Yu X, Dong K (2020) Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. https://doi.org/10.1136/bmjdrc-2020-001343

6. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, Wang S, Zheng C (2020) Clinical characteristics of 1195 severe patients with coronavirus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. https://doi.org/10.1007/s10150-020-01432-5

7. Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, Pieri TC, Valsecchi P, Piralla A, Seminari E, Di Matteo A, Novati S, Maiocchi L, Pagnucco L, Tirani M, Baldanti F, Mojoli F, Perlini S, Bruno R, TaskF TCISMP (2020) Clinical characterisation of coronavirus disease 2019 (COVID-19) in Italy: an analysis of 1692 molecular and cellular biochemistry. JAMA. https://doi.org/10.1001/jama.2020.6775

8. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Battista Perego G, Evasi G, Citerio G, Foti G, Natalini G, Merli M, Korsgren O, Undlien D, Eike MC, Richardson SJ (2015) Detection of a low-grade entero viral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes. 64:1682–1687

9. De Bree AO, Eizirik DL, Hanahan DJ (2016) Viral infections in type 1 diabetes mellitus—who are the beta cells? Nat Rev Endocrinol 12:263

10. Sarmiento L, Cubas-Dueñas I, Cabrera-Rode E (2013) Evidence of association between type 1 diabetes and exposure to enterovirus in Cuban children and adolescents. MEDICC Rev 15:29–32

11. Campbell IL, Kay T, Oxbrow L, Harrison L (1991) Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Investig 87:739–742

12. Christen U, Edelmann KH, McGavern DB, Wolfe T, Coon B, Teague MK, Miller SD, Oldstone MB, Von Herrath MG (2004) A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Investig 114:1290–1298

13. Principi N, Bertioli MG, Bianchini S, Esposito S, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Network M, Network M, Network M, Network M, Network M, Network M (2017) Type 1 diabetes and viral infections: what is the relationship? J Clin Virol 96:26–31

14. Yang J-K, Lin S-S, Ji X-J, Guo L-M (2010) Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 47:193–199

15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X (2020) Clinical features of patients with confirmed 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506

16. Cao X (2020) COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20:269

17. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis

18. Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 80:607

19. Wu D, Yang X (2020) TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fdetrinitin. J Microbiol Immunol Infect 53:368

20. McGonagle D, Sharif K, O’Regan A, Bridgewood C (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102537
27. Walker LS, von Herrath M (2016) CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol 183:16–29
28. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M (2011) Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903–2913
29. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F (2007) Development, cytokine profile and function of human interleukin-17-producing helper T cells. Nat Immunol 8:950–957
30. Reineert-Hartwall L, Honkanen J, Salo HM, Nieminen JK, Luopajärvi K, Härkönen T, Veijola R, Simell O, Ilenen J, Peet A (2015) Th1/Th17 plasticity is a marker of advanced β cell autoimmunity and impaired glucose tolerance in humans. J Immunol 194:68–75
31. Abdel-Moneim A, Bakery HH, Allam G (2018) The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother 101:287–292
32. Shoelsone SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180
33. Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709–716
34. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I—converting enzyme 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59:2540–2548
35. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A humoral homolog of angiotensin-converting enzyme cloning and functional expression as a carboxypeptidase. J Biol Chem 275:33238–33243
36. Li W, Moore MJ, Vasilieva N, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M (2011) Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903–2913
37. Lavoie JL, Sigmund CD (2003) Minireview: overview of the renin-angiotensin system. Circ Res 126:1456–1466
38. Higami R, Kiyomoto H, Nishiyama A (2007) Angiotensin II and oxidative stress. Curr Opin Cardiol 22:311–319. https://doi.org/10.1097/HCO.0b013e328202f45d
39. Benigni A, Cassis P, Remuzzi G (2010) Angiotensin II and oxidative stress. Curr Opin Cardiol 22:311–319. https://doi.org/10.1097/HCO.0b013e328202f45d
40. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A humoral homolog of angiotensin-converting enzyme cloning and functional expression as a carboxypeptidase. J Biol Chem 275:33238–33243
41. Li W, Moore MJ, Vasilieva N, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M (2011) Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903–2913
42. Wang J, Liu R, Qi H, Wang Y, Cui L, Wen H, Li Y, Yin C (2015) The ACE2-angiotensin-(1–7)-Mas axis protects against pancreatic acinar cell damage in cell culture. Pancreas 44:266–272
43. Yu X, Cui L, Hou F, Liu X, Wang Y, Cui L, Liu R, Yin C (2018) Angiotensin-converting enzyme 2 (ACE2) regulates pancreatic cell damage in cell culture. Pancreas 44:266–272
44. Roja-Ho H, Riera M, Palau V, Pascual J, Soler MJ (2017) Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 18:563
45. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QG, Backx PH, Penninger JM, Herzenberg AM, Scholey JW (2007) Loss of angiotensin-converting enzyme-2 (ACE2) accelerates diabetic kidney injury. Am J Pathol 171:438–451
46. Santos SHS, Fernandes LR, Mario ÉG, Ferreira AVM, Póto LJC, Alvarez-Leite JI, Botton LM, Bader M, Alenina N, Santos RAS (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57:340–347
47. Echeverría-Rodríguez O, Del Valle-Mondragón L, Hong E (2014) Angiotensin 1–7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. Peptides 51:26–30
48. Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA (2010) Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech 7:e135–e143. https://doi.org/10.1016/j.ddmech.2010.08.001
49. Dostal DE (2000) The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 91:1–11. https://doi.org/10.1016/s0167-0115(99)00123-8
50. Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachefiro V, Aguado A, Garcia-Redondo L, Barrus MT, de Batista PR, Briones AM, Salaises M, Alonso MJ (2015) Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol 172:3159–3176. https://doi.org/10.1111/bph.13117
51. Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21. https://doi.org/10.1016/S2213-2600(20)30116-8
52. Beger HG, Buchler M, Kozarek R, Lerch M, Neoptolemos JP, Warshaw A, Whitcomb D, Shiratori K (2009) The pancreas: an integrated textbook of basic science, medicine, and surgery. Wiley
53. Evans JL, Goldfine ID, Maddux BA, Groydsk GM (2003) Are oxidative stress—activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52:1–8
54. Tikellis C, Wooley PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53:989–997
55. Niu M-J, Yang J-K, Lin S-S, Ji X-J, Guo L-M (2008) Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 34:56–61
56. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I—converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59:2540–2548
57. Chhabra KH, Xia H, Pedersen KB, Speth RC, Lazartigues E (2013) Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice. Am J Physiol Endocrinol Metab 304:E874–E884
58. Shoemaker R, Yannikouris F, Thatcher S, Cassis L (2015) ACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice. Am J Physiol Endocrinol Metab 309:E621–E631
59. Wang J, Liu R, Qi H, Wang Y, Cui L, Wen H, Li Y, Yin C (2015) The ACE2-angiotensin-(1–7)-Mas axis protects against pancreatic cell damage in cell culture. Pancreas 44:266–272
60. Yu X, Cui L, Hou F, Liu X, Wang Y, Wen Y, Li H, Yin C (2015) The ACE2-angiotensin-(1–7)-Mas axis protects against pancreatic cell damage in cell culture. Pancreas 44:266–272
61. Lu C-L, Wang Y, Yuan L, Li Y, Li X-Y (2014) The angiotensin-converting enzyme 2/angiotensin (1–7)-Mas axis protects against pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-kB pathway. Int J Mol Med 41:409–420
62. Lee J, Goldfine ID, Maddux BA, Groydsk GM (2003) Are oxidative stress—activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52:1–8
63. Groß S, Jahn C, Cushman S, Bär C, Thum T (2020) SARS-CoV-2 receptor ACE2-dependent implications on the
cardiovascular system: from basic science to clinical implications. J Mol Cell Cardiol 144:47
64. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY (2014) Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 66:167–176. https://doi.org/10.1016/j.yjmcc.2013.11.017
65. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C (2009) Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 54:575–582. https://doi.org/10.1161/HYPERTENSIONAHA.108.127670
66. Pedersen KB, Chodavarapu H, Porretta C, Robinson LK, Lazar- tigues E (2015) Dynamics of ADAM17-mediated shedding of ACE2 applied to pancreatic islets of male db/db mice. Endocrinology 156:4411–4425
67. Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, DeFronzo RA, Abdul-Ghani MA (2011) The relationship between β-cell function and glyated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34:1006–1010
68. Hou X, Liu J, Song J, Wang C, Liang K, Sun Y, Ma Z, Yang W, Li C, Zhang X (2016) Relationship of hemoglobin A1c with β cell function and insulin resistance in newly diagnosed and drug naive type 2 diabetes patients. J Diabetes Res 20:16. https://doi.org/10.1155/2016/8797316
69. Marini M, Frontoni S, Succurro E, Arturi F, Sciacqua A, Hribal M, Perticone F, Sesti G (2014) Insulin sensitivity, and β-cell function in relation to hemoglobin A1C. Nutr Metab Cardiovasc Dis 24:27–33
70. Itzhaki Ben Zadok O, Kornowski R, Goldenberg I, Klempfner R, Marini M, Frontoni S, Succurro E, Arturi F, Sciacqua A, Hribal M, Perticone F, Sesti G (2014) Insulin sensitivity, and β-cell function in relation to hemoglobin A1C. Nutr Metab Cardiovasc Dis 16:102. https://doi.org/10.1186/s12933-017-0582-y
71. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nonidiabetic adults. N Engl J Med 362:800–811. https://doi.org/10.1056/NEJMoa0908359
72. Wang Z, Du Z, Zhu F (2020) Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 164:108214
73. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z (2020) SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 is expressed in human pancreatic islet β-cells and is upregulated by inflammatory stress. bioRxiv
74. Watanabe Y, Allen JD, Wrapp D, MeLLans J, Crispin M (2020) SARS-CoV-2 spike protein glycan shield: implications for immune recognition. bioRxiv
75. Brukszy A (2020) Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 92:770
76. Dokken BB (2008) The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes Spectrum 21:160–165. https://doi.org/10.2337/diaspect.21.3.160
77. Dushpanova A, Agostini S, Ciofini E, Cabiati M, Casieri V, Matteucci M, Del Ry S, Clerico A, Berti S, Lionetti V (2016) Gene silencing of endothelial von Willebrand Factor attenuates hyperglycemia by inflammatory stress. Molecular and Cellular Biochemistry (2022) 477:1681–1695
78. Zhou MS, Schulman IH, Yi H, Wang C (2020) Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care 8:1476
79. Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, Xu J, Wu F, Duan L, Yin Z (2020) Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 63:2102–2111
80. Ceriello A (2020) Hyperglycemia and COVID-19: what was known and what is really new? Diabetes Res Clin Pract 167:108
81. Zini E, Osto M, Franchini M, Guscetti F, Donath M, Perren A, Heller R, Linscheid P, Bouwman M, Ackermann M (2009) Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat. Diabetologia 52:336
82. TGC Registries, 2017–2018. Model 4: regression analysis. URL http://www.gis-anderssen.de (accessed 13 November 2019)
83. Donath MY, Ehres JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M (2005) Mechanisms of β-cell death in type 2 diabetes. Diabetes 54:S108–S113
84. Zhou MS, Schulman IH, Zeng Q (2012) Link between the renin-angiotensin system and insulin resistance: implications for cardio-vascular disease. Vasc Med 17:330–341. https://doi.org/10.1177/1358863X12450094
85. Rocca-Ho H, Palau V, Gimeno J, Pascual J, Soler MJ, Riera M (2020) Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice. Lab Invest 100:1169
86. Xuan X, Gao F, Ma X, Huang C, Wang Y, Deng H, Wang S, Li W, Yuan L (2018) Activation of ACE2/angiotensin (1–7) attenuates pancreatic β cell dedifferentiation in a high-fat-diet mouse model. Metabolism 81:83–96
87. Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Overbergh L, Gysemans C, Colli ML, Marchetti P (2020) SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 is expressed in human pancreatic islet β-cells and is upregulated by inflammatory stress. bioRxiv
88. Grant OC, Montgomery D, Ito K, Woods RJ (2020) Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition. bioRxiv
89. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang YY, Ma HL, Chen YP, Liu WY, George J, Zheng MH (2020) Letter to the editor: obesity as a risk factor for greater severity of COVID-19
in patients with metabolic associated fatty liver disease. Metabolism 108:154244. https://doi.org/10.1016/j.metabol.2020.154244

98. Caussy C, Pattou F, Wallet F, Simon C, Chalopin S, Telliam C, Mathieu D, Subtil F, Frobert E, Alligier M, Delaunay D, Vanhems P, Laville M, Jourdain M, Disse E, Consortium COH and Lille C-OSG (2020) Prevalence of obesity among adult patients with COVID-19 in France. Lancet Diabetes Endocrinol 8:562–564. https://doi.org/10.1016/S2213-8587(20)30160-1

99. Zhou Y, Chi J, Lv W, Wang Y (2020) Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. https://doi.org/10.1002/dmrr.3377

100. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y (2020) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 109:531–538. https://doi.org/10.1007/s00392-020-01626-8

101. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97:829–838. https://doi.org/10.1016/j.kint.2020.03.005

102. Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G (2020) COVID-19, hypertension and cardiovascular diseases: should we change the therapy? Pharmacol Res 158:104906. https://doi.org/10.1016/j.phrs.2020.104906

103. Awortwe C, Cascorbi I (2020) Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. Pharmacol Res. https://doi.org/10.1016/j.phrs.2020.105250

104. Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z, Zahra E, Mahboobeh R, Lionetti V (2021) Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. Heart Fail Rev 26:371–380. https://doi.org/10.1007/s10741-020-10016-2

105. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, Duarte-Neto AN, Soares Gomes-Gouvea M, Viu Degaspere N, Figueiredo Delgado A, Montanari Fiorita C, Nunes Leal G, Rodrigues RM, Taverna Chaim K, Rebello Pinho JR, Carneiro-Sampaio M, Mauad T, Ferraz da Silva LF, Brunow de Carvalho W, Saldiva PHN, Garcia Caldini E (2020) SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health 4:790–794. https://doi.org/10.1016/S2213-8587(20)30257-1

106. Li M, Dong Y, Wang H, Guo W, Zhou H, Zhang Z, Tian C, Du K, Zhu R, Wang L, Zhao L, Fan H, Luo S, Hu D (2020) Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis 30:1061–1067. https://doi.org/10.1016/j.numecd.2020.04.013

107. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 17:543–558. https://doi.org/10.1038/s41569-020-0413-9

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.